Magneto-polymeric nanosystems for rapid CTC targeting, detection & imaging. Patents | 22 April 2021 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Patent Details Related patent documents CA2976614 TH175113 WO/2016/132265 EP3259598 ES2828025 PL3259598 US20230408525 Granted Canadian, European and Indian Patent Actorius Innovations and Research Pvt. Ltd. View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover enables early cancer spread detection and faster diagnosis. | ET Health Press Release | 24 August 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… A team of Pune scientists have discovered a technology that can detect within mere hours, the spread of cancer and claim that the new finding reduces considerably the time taken for detecting the disease. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process. Presently, in India, the final diagnosis report to detect the spread of cancer takes about 12 days whereas, with OncoDiscover technology, doctors can detect it in a mere 3.5 hours. Dr Khandare told ANI, "We felt the need for this technology because global cancer is spreading. 90 per cent of the people get to know they have cancer when it is at the second stage but through this technology, we can try saving that 90 per cent. This technology is needed to detect cancer at an early stage." Read the Full Story on The Economic Times - https://health.economictimes.indiatimes.com/news/diagnostics/pune-scientists-develop-tech-to-detect-early-spread-of-cancer/70739264 Business Standards - https://www.business-standard.com/article/news-ani/pune-scientists-discover-tech-first-in-india-to-detect-early-spread-of-cancer-119082400816_1.html View full article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Comprehensive ctDNA and CTC profiling predicts metastasis in early breast cancer. Publications | 15 January 2023 AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Background Genomic profiling has revolutionized precision oncology, impacting diagnosis, prognosis, and therapy decisions. Considering the high spatiotemporal diversity and heterogeneity of breast tumor-cell genomes, small-gene panels often fail to capture rare but important genomic alterations. Conversely, comprehensive ctDNA sequencing approaches enable the identification of under-characterized 'long-tailed driver' genomic alterations and capture intra- and inter-metastatic heterogeneity. Here, we demonstrate the clinical utility of comprehensive genome profiling with higher sensitivity to predict the possibility of metastasis in early-stage breast cancer patients. Methods We retrospectively analyzed ctDNA and genomic DNA (gDNA) from FFPE samples, as well as circulating tumor cells (CTCs), in 10 treatment-naive, hormone-positive, and HER2-negative primary-stage breast cancer patients using the OncoIndx comprehensive 600-gene panel. The panel captures all important cancer-relevant genomic alterations, including tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD) prediction, and cfDNA tumor fraction (TF). CTCs were enumerated from 1.5 ml of blood using the OncoDiscover platform, approved by the Drug Controller General of India, using anti-EpCAM antibody-mediated immunomagnetic nanoparticles. CTCs were confirmed for cytokeratin 18+ and DAPI+ markers, and the absence of CD45. Results The comprehensive genomic profile obtained from ctDNA and gDNA from the FFPE of early-stage breast cancer patients predominantly exhibited the presence of alterations in PIK3CA and ESR1 signaling pathways. PIK3CA mutations were present in 77% and 44% of baseline ctDNA and gDNA samples, while ESR1 mutations were present in 44% and 22% of baseline ctDNA and gDNA, respectively. In addition, we observed about 70% additional driver mutations in ctDNA samples, suggesting the shedding of ctDNA together with CTCs (80% positive) as a likely positive biomarker of metastasis. About 50% of the patients showed higher TMB and HRD. Notably, TF representing ctDNA varied between 13% to 27% in blood samples with a corresponding ploidy range of 2.9 to 4.7. Surprisingly, ~50% of the patient population matched the mutation profile of clinically confirmed metastatic patients. All the patients harboring potential metastatic driver alterations showed the presence of CTCs in peripheral blood. Conclusions Comprehensive ctDNA genomic profiling showed potential metastasis-driving alterations, suggesting the role of ctDNA-based liquid biopsy to predict metastasis in early breast cancer patients. We observed enhanced TF at the time of diagnosis, possibly due to the presence of distant metastasis, high disease burden, and aggressive tumor biology. Our results suggest that ctDNA dynamics at the time of disease presentation can predict early metastasis and may demonstrate the divergent response of tumor heterogeneity to treatment in early-stage breast cancer. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Accounts Manager Publication Date: 26 Aug 2026 | Last Application Date: 6 Oct 2026 Apply Now Department Finance & Accounts Location Pune, India Experience 5–10 years Role Overview The Accounts Manager will be responsible for managing the day-to-day accounting and financial operations of Actorius. The role will oversee financial records, reporting, compliance, receivables, payables and coordination with internal and external stakeholders. Key Responsibilities Manage day-to-day accounting operations and financial transactions. Maintain accurate books of accounts and financial records. Oversee accounts payable and accounts receivable. Manage invoicing, payments, receipts and reconciliations. Prepare monthly, quarterly and annual financial reports. Monitor receivables, outstanding payments and collections. Coordinate with auditors, consultants, banks and other financial stakeholders. Ensure timely statutory and tax-related compliance. Support GST, TDS and other applicable regulatory requirements. Prepare MIS reports and financial statements for management review. Monitor expenses, budgets and cash-flow requirements. Establish and maintain appropriate financial controls. Support internal and external audits. Identify discrepancies and ensure timely resolution. Work closely with other departments on financial and operational requirements. Maintain confidentiality and integrity of financial information. Qualifications & Skills Bachelor's degree in Commerce, Accounting, Finance or a related field. CA/Inter-CA, CMA, MBA Finance or equivalent qualification is an advantage. 5–10 years of relevant experience in accounting and finance. Strong knowledge of accounting principles, GST, TDS and statutory compliance. Experience with accounting software/ERP systems and MS Excel. Strong analytical, organizational and problem-solving skills. High attention to detail and accuracy. What We Look For At Actorius, we value people who combine ownership, curiosity, scientific thinking and execution . We look for professionals who are: Passionate about healthcare and meaningful innovation. Comfortable working in a fast-growing, innovation-driven environment. Curious and willing to learn. Strong in communication and collaboration. Focused on outcomes and accountability. Comfortable working across functions. Ethical and professional in their approach. Motivated by the opportunity to contribute to technologies that can impact cancer care. About Actorius Actorius Innovations & Research Pvt. Ltd. is an innovation-driven biotechnology and medical diagnostics company focused on developing technologies that address critical challenges in cancer care. From breakthrough research to clinically meaningful diagnostics, Actorius works at the intersection of biotechnology, biomaterials, circulating tumor cells (CTCs), liquid biopsy and oncology diagnostics . Our goal is to translate deep scientific understanding into practical technologies that can help clinicians make more informed decisions and improve patient outcomes. Our flagship OncoDiscover® CTC Test is India's first DCGI/CDSCO-approved blood test for detecting circulating tumor cells and supporting cancer monitoring. Actorius also continues to develop advanced technologies such as OncoMetastat® , alongside its broader research and diagnostic platforms. We are looking for dynamic thinkers, problem-solvers and doers who want to work on meaningful challenges in healthcare and contribute to technologies that can make a difference in cancer care. Why Join Actorius? Work on Meaningful Healthcare Challenges Contribute to technologies focused on cancer diagnostics, CTCs, liquid biopsy and oncology. Be Part of an Innovation-Driven Organisation Work alongside scientists, clinicians, business leaders and healthcare professionals. Learn Across Disciplines Actorius encourages interdisciplinary thinking across science, technology, diagnostics, marketing, sales and operations. Build With Purpose Our work is driven by the belief that better biological insights can contribute to better healthcare decisions. Grow With the Organisation Join a growing team where ownership, initiative and individual contribution matter. How to Apply Click the below link to apply. Candidates are encouraged to clearly mention the position and preferred location in their application. Apply Now

The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey - Dr Jayant Khandare Press Release | 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. It takes just one cell to restart the story. In a thought-provoking insight into cancer progression, Dr. Jayant Khandare, Co-founder of Actorius Innovations and a leading researcher in circulating tumor cells, asks a pivotal question: “Can a single cell restart the cancer journey?” 🔗 Read the featured articles: English Article: https://english.dainikjagranmpcg.com/education/6a1285a923ea1/article-19162 Hindi Article: https://www.dainikjagranmpcg.com/national-international/the-hidden-danger-of-a-single-cell-dr-jayant-khandare/article-54101 Explore more research publications: https://www.actorius.in/newsroom #Actorius #DrJayantKhandare #CancerResearch #OncologyInnovation #LiquidBiopsy #OncoDiscover #CancerDiagnostics #HealthcareInnovation #PrecisionMedicine #CTC #CancerAwareness #MedicalResearch #Biotechnology #EarlyDetection #CancerCare Read Article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Chemo-specific designs for the enumeration of CTCs: advances in liquid biopsy Publications | 18 December 2020 Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Advanced materials and chemo-specific designs at the nano- and micrometer scale have ensured revolutionary progress in next-generation clinically relevant technologies. For example, isolating a rare population of cells, such as circulating tumor cells (CTCs) from blood among billions of other blood cells, is one of the most complex scientific challenges in cancer diagnostics. Achieving this level of exceptional specificity for extracellular biomarker interactions requires chemical tunability through the use of advanced materials and multistep reactions in both solution and insoluble states. This review delineates the chemo-specific substrates, chemical methods, and structure–activity relationships (SARs) of chemical platforms used for the isolation and enumeration of CTCs, thereby advancing the relevance of liquid biopsy in cancer diagnostics and disease management. We highlight the synthesis of cell-specific, tumor biomarker-based chemo-specific substrates utilizing functionalized linkers through chemistry-based conjugation strategies. The capacity of these nano- and micro-scale substrates to enhance interaction specificity and efficiency with targeted tumor cells is discussed in detail. Furthermore, this review emphasizes the importance of CTC capture and downstream processes involving genotypic and phenotypic CTC analysis in real time. These approaches enable early detection of metastasis progression, evaluation of chemotherapy treatment response, and monitoring of progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS) in cancer patients. Royal Society of chemistry. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

AACR 2026 - Actorius Innovations and Research Events | 23 April 2026 AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Highlights from AACR 2026 We exhibited and presented two scientific posters that highlight the evolving role of circulating tumor cells (CTCs) in cancer progression and management: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients. Depletion of circulating tumor cells using an automated device with non-hemolytic affinity-based substrates These studies reflect our continued efforts to better understand CTC biology—not only as indicators, but as active contributors to metastasis. At the center of this work is OncoMetastat® , our patented investigational extracorporeal blood-processing platform. It is envisaged to selectively capture and study circulating tumor cells from a patient’s bloodstream while maintaining blood integrity. Designed with a strong focus on precision and safety, the current prototype is under evaluation for its potential relevance in metastasis research and broader cancer management. Some Interesting Clicks Video Highlights We look forward to engaging with researchers, clinicians, and innovators shaping the future of oncology. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dynamic device captures CTCs safely, enabling monitoring and metastatic control. Publications | 3 June 2025 Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Background Primary tumors are known to shed circulating tumor cells (CTCs), promoting systemic dissemination and increasing the risk of metastasis to distant organs. Approximately 90% of cancer-related deaths are directly associated with metastasis. Several studies in animal models suggest improved overall survival following reduction in the number of CTCs in circulation. In this study, we demonstrate the capture of CTCs using a continuous blood-flow device incorporating three-dimensional glass substrates (3D GS) conjugated with affinity ligands, including anti-epithelial cell adhesion molecule (EpCAM) antibody and transferrin (Tf), in cancer patients. Methods A bi-spiral, plano-horizontal, optically transparent device fabricated from biocompatible resin with multiple channels for continuous blood flow was designed using a 3D printer. The circulation device comprised 14 loops capable of holding 17.5 mL of blood and containing 680 glass substrates (2 mm diameter) conjugated with anti-EpCAM antibody and transferrin. The system was mechanized for functional circulation using three pumps. Pyrogenicity resulting from blood passage through the device was evaluated in three New Zealand White rabbits according to ISO:10993-11 guidelines for systemic toxicity assessment. Additionally, 27 blood samples from patients with early- and late-stage cancers across nine cancer types, including colorectal, lung, breast, and ovarian cancers, were processed using the OncoDialysis assay. The cohort consisted of 48.15% male and 51.85% female patients. CTCs were captured using five glass substrates from 1.5–5 mL of blood and validated using CK18 and CD45 markers through fluorescence microscopy. Samples were also analyzed using the Drug Controller, India–approved OncoDiscover technology for comparative evaluation. Results No hemolysis was observed as a result of the device. Continuous circulation of up to 5 mL of blood successfully demonstrated CTC capture within the flow system. All rabbits remained healthy during testing, and none exhibited an individual temperature increase of 0.5°C or more compared with controls, indicating no systemic toxicity. The OncoDialysis assay detected CTCs in 48.15% of patients (n = 13/27), yielding a total of 14 CTCs (12 single CTCs and 2 clusters), with a mean CTC distribution of 0.51 per 1–5 mL of blood. The OncoDiscover platform isolated 23 CTCs (18 single CTCs and 5 clusters), with a mean CTC distribution of 0.8. A concurrence rate of 74.07% was observed between the two platforms. In 40.74% of cases (n = 11/27), CTCs were detected by both systems. Conclusions We developed a dynamic in vitro blood circulation device with demonstrated safety in animal studies, capable of selectively capturing circulating tumor cells from patient blood. Reduction of CTC burden may hold significant therapeutic potential in limiting metastatic spread and improving overall survival in epithelial-origin cancers, both in treated and untreated settings. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Publications | 27 April 2022 Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Wearable, point-of-care diagnostics, and biosensors are on the verge of bringing transformative changes in detection, management, and treatment of cancer. Bioinspired materials with new forms and functions have frequently been used, in both translational and commercial spaces, to fabricate such diagnostic platforms. Engineered from organic or inorganic molecules, bioinspired systems are naturally equipped with biorecognition and stimuli-sensitive properties. Mechanisms of action of bioinspired materials are deeply connected with thermodynamically or kinetically controlled self-assembly at the molecular and supramolecular levels. Thus, integration ofbioinspired materials into wearable devices, either as triggers or sensors, brings about unique device properties usable for detection, capture, or rapid readout for an analyte of interest. In this review, we present the basic principles and mechanisms of action of diagnostic devices engineered from bioinspired materials, describe current advances, and discuss future trends of the field, particularly in the context of cancer. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

N-Cadherin CTC capture identifies EMT-CTCs linked to metastasis and treatment resistance. Publications | 30 August 2026 Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes. Introduction: Epithelial-to-mesenchymal transition (EMT) enables tumour cells to lose epithelial characteristics, acquire enhanced motility and aggressive invasiveness, and activate metastatic dissemination. Circulating tumour cells (CTCs) undergoing true EMT possess greater metastatic potential than purely epithelial CTCs because they exhibit increased survival in the bloodstream, immune evasion, and the ability to colonise distant organs. Thus, detection and characterization of EMT-CTCs provide clinically valuable insights into metastatic risk, disease progression, and treatment resistance beyond conventional epithelial CTC enumeration. Here, we report an N-Cadherin affinity-based ligand CTC-capture platform for capturing CTCs demonstrating varied EMT-CTC phenotypes. Methods: Retrospectively, we analyzed blood samples from 30 cancer patients, including colorectal cancer stages I–IV (n=9), breast/TNBC (n=7), advanced lung adenocarcinoma (n=2), pancreatic cancer, anaplastic thyroid cancer, endometrial cancer, head and neck cancer, melanoma, and others. The cohort comprised 18 female and 12 male patients aged 19–84 years. We first validated Vimentin-positive MCF-7 cells using the OncoMetastat platform containing N-Cadherin glass beads for cellular localization. CTCs were captured using N-Cadherin glass beads from 1.5 mL of blood and subsequently confirmed based on Vimentin+, DAPI+, N-Cadherin+, and CD45− expression using a Nikon Ti-2 fluorescence microscope. Results: Vimentin-positive CTCs were detected in 27/30 (90%) cancer patient blood samples. A total of 42 CTCs were captured, with a mean distribution of approximately 1.4 CTCs per sample and a range of 1–3 CTCs. Among the isolated CTCs, 13/42 (30.9%) expressed cellular N-Cadherin. Importantly, N-Cadherin expression was observed in 5/10 (50%) colorectal cancer (CRC) samples and 3/7 (42.8%) breast cancer samples. In six patients, intra-CTC heterogeneity was observed, with both N-Cadherin-positive and N-Cadherin-negative CTCs. The MCF-7 cell study demonstrated >90% cell capture using the N-Cadherin affinity platform, with Vimentin localization. Conclusion: We demonstrate the capture of true epithelial-to-mesenchymal transitioning CTCs using an affinity-based N-Cadherin system in cancer patients. Further studies are required to investigate comparative CTC detection using anti-EpCAM antibodies and N-Cadherin, as well as their association with clinical outcomes. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Non-hemolytic adsorbents for toxin isolation, disease tracking & therapy efficacy. Patents | 20 October 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Patent Details The present disclosure relates to non-hemolytic adsorbent compositions useful for isolating, enumerating, accounting, and removing the disease-causing toxic constituents in the blood. The said compositions are useful in identifying the disease, disease status, and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease. Methods for isolating, enumerating, accounting, and removing disease-causing toxic constituents in the blood as well as monitoring the disease status and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease are disclosed. Related patent documents US20210106742 WO/2021/074786 CA3154234 IN202044044657 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover our groundbreaking research in Oncology. Explore our publications to see research that matters. Stay informed with our latest insights. Publications Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 1 Sept 2026 Longitudinal Assessment of Circulating Tumor Cells Expressing PD-L1 and Clusters in Esophageal Cancer Patients A longitudinal study of 110 esophageal cancer patients evaluated CTCs, PD-L1 expression, and CTC clusters, highlighting their potential as predictive biomarkers for treatment outcomes and occult minimal cellular residual disease. Read More 30 Aug 2026 Comparative Analysis of Circulating Tumor Cells, Clusters, and PD-L1 Expression in Paired Peripheral and Portal Venous Blood with Solid Malignancies A prospective study compares circulating tumor cells, CTC clusters, and PD-L1 expression in paired peripheral and portal venous blood, highlighting compartment-specific differences and the potential of dual-compartment liquid biopsy profiling. Read More 30 Aug 2026 Assessment of apprehension for Minimal Cellular Residual Disease Using Circulating Tumour Cells in Pre and Post Surgery Breast Cancer Patients A prospective study evaluates RUPIKA, a structured CTC-based MRD disclosure protocol, showing significantly reduced cancer worry among breast cancer patients after surgery compared with routine result communication. Read More 30 Aug 2026 Algorithm based analysis of circulating tumour cells in cancer patients A study evaluating CellMatrics, a Python-based automated image analysis algorithm for CTC detection, demonstrated rapid and robust concordance with manual CTC analysis across blood samples from 32 cancer patients. Read More 30 Aug 2026 Detection of Androgen Receptor Splice Variant 7 in Circulating Tumor Cells for Dynamic Treatment Decision in Prostate Cancer Patients This study evaluated AR-V7 in CTCs and clusters from prostate cancer patients, highlighting its potential to predict ARSI resistance and support dynamic treatment decisions. Read More 30 Aug 2026 Capture of Cancerous Cells and Overall Survival in Rats using Ex-vivo Extracorporeal Device in Multiple Onco-dialysis Cycles An animal study evaluated OncoMetastat for ex-vivo cancer cell capture, safety, and survival in rats. Across multiple onco-dialysis cycles, cancer cells were captured, all test-group rats survived 14 days, and histopathology showed normal tissues. Read More 30 Aug 2026 Capture of Epithelial-Mesenchymal Transitioning Circulating Tumor Cells using Affinity Based N-Cadherin System A study demonstrating N-Cadherin affinity-based capture of EMT-associated CTCs in diverse cancers, with Vimentin-positive CTC detection in 90% of samples and N-Cadherin expression revealing heterogeneous metastatic phenotypes. Read More 30 Aug 2026 Evaluation of circulating tumor cells expressing PD-L1 and CTC clusters at baseline and follow ups in triple-negative breast cancer A retrospective study of 180 TNBC blood samples evaluated CTC burden, PD-L1 expression and CTC clusters using the CDSCO-approved OncoDiscover platform, highlighting their potential for longitudinal disease monitoring and biomarker-guided management. Read More 17 Mar 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 Mar 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 Mar 2026 ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 Mar 2026 AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 Mar 2026 ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 Mar 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 7 Mar 2026 AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 27 Jan 2026 Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 Nov 2025 PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients This study demonstrates a high prevalence of CTCs in the endometrial cancer population. The presence of CTCs, CTC clusters, and PD-L1–overexpressing CTCs indicates occult minimal residual disease, disease aggressiveness, and potential progression toward metastasis. Read More 3 Nov 2025 Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 Nov 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 Nov 2025 Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More 17 Oct 2025 Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Read More 16 Sept 2025 PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Read More 16 Sept 2025 Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. Read More 3 Jun 2025 PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Read More 3 Jun 2025 Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Read More 3 Jun 2025 Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Read More 3 Jun 2025 Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. Read More 3 Jun 2025 Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Read More 9 May 2025 Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Read More 14 Mar 2025 Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Read More First Prev 1 Page 1 Next Last